Skin Cancer Research Report SWAG SSG Maxine Taylor Senior Research Delivery Manager 17/05/2016
Clinical Research Network: West of England Prof Hugh Barr: Cancer Divisional Clinical Lead National and local engagement for whole cancer portfolio Dr Christopher Herbert: Skin Cancer Specialty Lead Represents WE at national skin CSG annual meeting Local engagement with clinicians regarding network wide approach to skin cancer portfolio and recruitment Maxine Taylor: Senior Research Delivery Manager Local oversight of cancer portfolio and performance Linking in with all networks and national teams Richard Munday: Cancer Portfolio Facilitator Preparation of reports on behalf of local teams and specialty leads Circulation of new studies Expert re EDGE database, ODP database
National cancer research objectives Every network to deliver a portfolio of studies that include ‘challenging’ studies in support of national cancer priorities: Cancer surgery: 4 recruits per 100,000 population Radiotherapy: 6 recruits per 100,000 Rare cancers: 12 recruits per 100,000 Children: 3 per 100,000 16-25 age group: collect baseline information
This year’s portfolio Short Name Gloucestershire Hospitals NHS Foundation Trust NORTH BRISTOL NHS TRUST UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST Grand Total CANC - 3574 - Nivolumab for Subjects with Histologically Confirmed Stage III or Stage IV Melanoma 1 CANC - 3678 Nivolumab and/or Ipilimumab in Melanoma MelMarT - Melanoma Margins Trial - Pilot Study NCRN442 BRIM 8: Vemurafenib in adjuvant melanoma NCRN492 NEMO - MEK162 vs dazcarbazine in advanced NRAS melanoma EORTC E18081 –adjuvant PEG-Interferon x 2 years vs surveillance after resection of higher risk ulcerated and node negative melanomas 4 5
EORTC studies open 1325 Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, double- blind Phase 3 trial of the EORTC Melanoma Group 1208 Minitub: Prospective registry on Sentinel Node (SN) positive melanoma patients with minimal SN tumor burden who undergo Completion Lymph Node Dissections (CLND) or Nodal Observation. 18081 Adjuvant peginterferon alpha-2b for 2 years vs Observation in patients with an ulcerated primary cutaneous melanoma with T(2-4)bN0M0: a randomized phase III trial of the EORTC Melanoma Group
EORTC study in set up SPECTAmel: Screening Patients with melanoma tumors for Efficient Clinical Trial Access Trial Status Regulatory in process Dates Date of activation: Data management at EORTC Full Phase Randomized trial Type - Targeted Sample size EORTC Groups: - - All Groups: 700 Number of steps 1 Drug Study Staff Caroline Robert Study Coordinator - Gustave Roussy, Villejuif Stefan Suciu Statistician - EORTC Headquarters, Brussels Sandrine Marreaud Coordinating Physician - EORTC Headquarters, Brussels Aline Gheeraert Project Manager - EORTC Headquarters, Brussels aline.gheeraert (at) eortc.be - +32 27741506 Type of cancer Melanoma Uveal Melanoma Participating Groups EORTC Melanoma Group(Coordinating Group) Protocol summary ClinicalTrials.gov NCT number NCT02507947 EudraCT
Contact & reference details Maxine.taylor@nihr.ac.uk Hugh.barr@glos.nhs.uk Christopher.herbert@uhbristol.nhs.uk http://csg.ncri.org.uk/portfolio-maps/ https://www.edge.nhs.uk/Account/Index?ReturnUrl=%2f http://www.crn.nihr.ac.uk/can-help/funders-academics/nihrcrn-portfolio/